Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28035577 | 0.92 | TSHR (0.52) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL2595476 | 0.92 | TSHR (0.52) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL317846 | 0.82 | TSHR (0.54) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL5250835 | 0.81 | TSHR (0.58) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL18191271 | 0.81 | TSHR (0.58) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL14198598 | 0.80 | TSHR (0.52) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL7966127 | 0.79 | TSHR (0.56) | TSHRALDH1A1CA12CA14KMT2A | |
| SCHEMBL659218 | 0.79 | TSHR (0.56) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL16288751 | 0.79 | TSHR (0.56) | TSHRLMNAALDH1A1CA12CA14 | |
| SCHEMBL7551344 | 0.79 | TSHR (0.56) | TSHRLMNAALDH1A1CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103664605-B | The preparation method of bromo-5,7, the 15-tri-alkynes-17-alkene stearic acid esters of bromination yne compounds E-18- | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-12-09 | — | — | CN | disclosed |
| WO-2014040477-A1 | PROCESS FOR PREPARING BROMINATED ENYNE COMPOUND E-18-BROMO-5,7,15-TRIYNE-17-ENE OCTADECANOIC ACID ESTER | 中国科学院上海药物研究所 (CN) | 2014-03-20 | — | — | WO | disclosed |
| US-6310257-B2 | ACIDOLYSIS OF EPOXIDE COMPOUND TO FORM CYCLOPENTENE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2001-10-30 | — | — | US | disclosed |
| US-20010012907-A1 | Substituted cyclopentene derivatives and method for preparing the same | NISSAN CHEMICAL INDUSTRIES, LTD. | 2001-08-09 | — | — | US | disclosed |
| US-6191291-B1 | OXIDATION OF A SUBSTITUTED CYCLOPENTADIENE DERIVATIVE WITH AN OXIDIZING AGENT TO FORM OXIRANE RING CONTAINING SUBSTITUTED CYCLOPENTADIENE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012907-A1 | Substituted cyclopentene derivatives and method for preparing the same | ACOX3, ACOX1, CBR1 | TSHR 2128/4885LMNA 1107/4885ALDH1A1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.